Non-Invasive Liver Diagnostic Index Reliability Analysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current non-invasive diagnostic tests for liver diseases, such as those using Fibroscan, suffer from inaccuracies leading to patient misclassifications due to abnormal, inconsistent, or non-homogeneous data, which affects the reliability and accuracy of fibrosis staging.

Innovation Solution

A method that collects an Initial Index from non-invasive tests like FibroMeter, analyzes its reliability by identifying abnormal or inconsistent data, and generates Event Alerts to replace or adjust the data, resulting in a Final Index that improves diagnostic accuracy by suppressing or substituting problematic data with mean values to enhance the Dispersion Index, thereby improving test reliability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If non-invasive diagnostic tests are used to assess liver fibrosis, then patient comfort and cost are improved, but diagnostic accuracy and reliability deteriorate due to false-positive or false-negative results

Engineering Contradiction:
Improvepatient comfortVSAvoiddiagnostic accuracy
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent implements a feedback mechanism where the initial diagnostic index is evaluated for reliability, and if unreliable, the system automatically requests additional measurements or alternative tests. This closed-loop feedback system continuously improves diagnostic accuracy by learning from initial results and adjusting the diagnostic pathway accordingly, resolving the contradiction between ease of operation and reliability.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent performs preliminary reliability assessment of the initial index before final diagnosis is made. By evaluating data quality, consistency, and homogeneity in advance, the system can identify potentially unreliable results early and trigger appropriate corrective actions, preventing false diagnoses while maintaining the non-invasive approach.

Inventive Principle:
Principle #10Preliminary action

2Device complexity

If non-invasive diagnostic tests are used to assess liver fibrosis, then invasiveness and cost are reduced, but measurement accuracy deteriorates due to errors from markers, practitioners, or patients

Engineering Contradiction:
ImproveinvasivenessVSAvoidmeasurement accuracy
Core Design Contradiction:
Device complexityVSMeasurement precision

Solution Approach 1:

The patent monitors and evaluates multiple parameters including the dispersion index, reliability predictors, and data consistency metrics. By changing and comparing these parameters, the system can detect measurement errors and distinguish between true diagnostic results and artifacts caused by measurement variability, thereby improving measurement precision without increasing invasiveness.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent introduces an intermediary reliability evaluation layer between the initial measurement and the final diagnosis. This intermediary system assesses data quality using multiple criteria (dispersion index, consistency, homogeneity) and acts as a mediator to filter out erroneous measurements before they affect the final diagnostic conclusion, thus improving measurement precision while maintaining device simplicity.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If reliability analysis is performed on initial index data, then diagnostic accuracy is improved, but computational complexity and time increase

Engineering Contradiction:
Improvediagnostic accuracyVSAvoidcomputational complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the reliability analysis into distinct, modular components: dispersion index calculation, consistency evaluation, homogeneity assessment, and reliability predictor analysis. Each component is independently calculated and evaluated, allowing the system to process reliability information in manageable steps without overwhelming computational complexity, thus improving diagnostic accuracy while controlling system complexity.

Inventive Principle:
Principle #1Segmentation

4Reliability

If multiple reliability criteria are evaluated (dispersion index, consistency, homogeneity), then test reliability is improved, but processing time and complexity increase

Engineering Contradiction:
Improvetest reliabilityVSAvoidprocessing time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary calculations of reliability metrics (dispersion index, consistency, homogeneity) during the initial data collection phase rather than as separate post-processing steps. By preparing these reliability indicators in advance alongside the primary measurements, the system minimizes additional processing time while maintaining comprehensive reliability evaluation.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP2872031B1Method for providing reliable non-invasive diagnostic tests
Publication Date: 2018.06.20 UNIVERSITE D ANGERS
  • EP2872031B1 patent drawingFigure 1
  • EP2872031B1 patent drawingFigure 2
  • EP2872031B1 patent drawingFigure 3A~3B

AI summary

Computerised system, especially in the form of an expert system, for evaluating combined diagnostic scores for liver disease and increasing accuracy of diagnosis using non-parametric sensitivity analysis based on analysis of variance and ROC curves to eliminate unreliable parameters from the model.